Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Lumosa Therapeutics and CHI Memorial announce new study for acute stroke 2024-02-02 22:22
Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke 2021-08-03 22:48
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA 2020-12-21 22:08
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US 2019-12-03 17:36
Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke 2019-06-13 20:00
Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals 2018-01-16 18:22
First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke 2017-08-01 09:46
1